FILTER

Refine your search with the following facets to narrow down your results.

25,927 Current news

Alnylam Granted Broad European Patent Covering Compositions, Methods and Uses for RNAi Therapeutics

13-May-2005 - Alnylam Pharmaceuticals, Inc. announced that the European Patent Office has granted Alnylam a new patent (EP Patent No. 1214945) with broad claims covering short interfering RNAs (siRNAs), the molecules that mediate RNA interference (RNAi). The new patent significantly extends the claims of the ...

Alnylam nucleotides patents +1

deCODE Paper Describes Efficacy of DG031 in Controlling Key Indicators of Risk for Heart Attack

13-May-2005 - deCODE genetics announced the publication of a landmark article by a team of its scientists presenting the results of Phase II clinical studies of DG031, the company's lead compound being developed for the prevention of myocardial infarction, or heart attack. The results demonstrate that DG031 ...

acute myocardial infarction biology biomarkers +10

Targeted Genetics Announces New Patent for Hyperlipidemia

13-May-2005 - Targeted Genetics Corporation announced issuance of U.S. patent #6,887,463, entitled, "Methods and Compositions for Gene Therapy for the Treatment of Defects in Lipoprotein Metabolism." This patent covers adenovirus AAV (Ad-AAV) hybrid vectors encoding the receptor for very low density ...

adenovirus cholesterol density +3

NIH funding helps PNNL researchers study bacteria that commonly attack cystic fibrosis patients, and tumor development

13-May-2005 - Two National Institutes of Health grants, totaling nearly $3 million, aim to alleviate painful conditions that affect millions of Americans. For cystic fibrosis patients, the research will be used to fight against infections caused by an aggressive bacterium called Pseudomonas aeruginosa that can ...

antibiotics bacteria cystic fibrosis +8

PerkinElmer and University of Copenhagen Announce Licensing Agreement for New Maternal Health Marker ADAM12

13-May-2005 - PerkinElmer Inc. has entered into a global licensing agreement with the University of Copenhagen in Copenhagen, Denmark, to develop assay kits for the biochemical marker ADAM12. ADAM12 has broad potential in maternal health screening as a marker for fetal chromosomal abnormalities as well as for ...

Denmark license agreements PerkinElmer +1

Dow and Cytogen Agree to Develop PSMA Antibody for Treatment of Cancer

12-May-2005 - Cytogen Corporation and DowpharmaSM contract manufacturing services, a business unit of The Dow Chemical Company, announced a collaboration to create a targeted oncology product designed to treat prostate and other cancers. Under the agreement, Dowpharma's proprietary MeO-DOTA bifunctional ...

clinical trials Dow Dow Chemical +7

Array BioPharma Receives Milestone Payment From Amgen

12-May-2005 - Array BioPharma Inc. announced that it has received a $1,000,000 research milestone payment from Amgen Inc. The payment resulted from a drug discovery agreement initiated between Amgen and Array in January 2002. To date, Array has received $1,420,000 in total milestone payments from Amgen under ...

Amgen milestone payments

BTI researcher gets NSF grant to create mutant maize lines for research

12-May-2005 - A Boyce Thompson Institute (BTI) researcher at Cornell University has received a grant to help assemble a unique database of DNA mutations in maize (corn). The project not only will allow researchers to study the effects of knocking out the function of single genes, one at a time, but also will ...

agriculture biology biotechnology +8

Genta and Aventis Terminate Genasense® Agreements

12-May-2005 - Genta Incorporated announced that Genta and Aventis, part of the sanofi-aventis Group, have signed an agreement to terminate their development and commercialization collaboration for Genasense® (oblimersen sodium injection). On November 8 2004, Aventis had provided Genta notice of termination of ...

Aventis clinical trials prostate cancer +2

Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of Novel Anti-Obesity Compound

12-May-2005 - Arena Pharmaceuticals, Inc. announced positive top-line results from its Phase 2 clinical trial of APD356, Arena's orally administered, internally discovered drug candidate for the treatment of obesity. Over the 28 day treatment period, there was a highly statistically significant (p=.0002) ...

Bio-Medical Research cardiovascular diseases clinical trials +5